AAPL330.49+5.53 (+1.70%) ▲|ABBV260.68-1.04 (-0.40%) ▼|ABT108.84-1.63 (-1.48%) ▼|ACN193.90+6.22 (+3.31%) ▲|ADBE286.31+6.52 (+2.33%) ▲|AMAT435.32-3.14 (-0.72%) ▼|AMD455.80-1.26 (-0.28%) ▼|AMGN442.90+0.06 (+0.01%) ▲|AMT177.25+4.33 (+2.50%) ▲|AMZN258.65+3.67 (+1.44%) ▲|AVGO347.54-19.70 (-5.36%) ▼|AXP330.52+0.54 (+0.16%) ▲|BA207.07-1.80 (-0.86%) ▼|BAC63.11+0.51 (+0.81%) ▲|BKNG198.54-1.06 (-0.53%) ▼|BLK1,116.05+8.97 (+0.81%) ▲|BMY67.55-0.12 (-0.17%) ▼|BNY164.22+2.18 (+1.34%) ▲|BRK-B507.61+2.37 (+0.47%) ▲|C137.73+3.39 (+2.52%) ▲|CAT801.00+8.72 (+1.10%) ▲|CL90.27+0.17 (+0.19%) ▲|CMCSA26.59-0.23 (-0.84%) ▼|COF218.97+2.37 (+1.09%) ▲|COP137.07-0.13 (-0.09%) ▼|COST927.05-1.43 (-0.15%) ▼|CRM264.22+7.29 (+2.84%) ▲|CSCO109.37-0.09 (-0.08%) ▼|CVS97.60+0.37 (+0.38%) ▲|CVX213.02+1.24 (+0.59%) ▲|DE692.91-5.46 (-0.78%) ▼|DHR208.92-0.99 (-0.47%) ▼|DIS107.82-0.16 (-0.15%) ▼|DUK121.56+1.00 (+0.83%) ▲|EMR149.58+0.60 (+0.40%) ▲|FDX320.38+3.84 (+1.21%) ▲|GD362.48-1.59 (-0.44%) ▼|GE332.37+2.87 (+0.87%) ▲|GEV945.25+23.31 (+2.53%) ▲|GILD149.98+0.37 (+0.24%) ▲|GM86.26+1.39 (+1.64%) ▲|GOOG339.54+5.76 (+1.73%) ▲|GOOGL343.03+5.91 (+1.75%) ▲|GS1,036.64+32.22 (+3.21%) ▲|HD317.86+1.68 (+0.53%) ▲|HON206.83+0.76 (+0.37%) ▲|IBM235.25+3.55 (+1.53%) ▲|INTC90.14+0.09 (+0.10%) ▲|INTU349.34+6.40 (+1.87%) ▲|ISRG368.79-3.09 (-0.83%) ▼|JNJ278.07+2.86 (+1.04%) ▲|JPM361.62+5.40 (+1.52%) ▲|KO88.92+0.68 (+0.77%) ▲|LIN483.75-2.10 (-0.43%) ▼|LLY1,152.68-7.41 (-0.64%) ▼|LMT530.78-0.77 (-0.14%) ▼|LOW200.94+1.10 (+0.55%) ▲|LRCX286.57-1.75 (-0.61%) ▼|MA587.11-1.04 (-0.18%) ▼|MCD258.47-2.48 (-0.95%) ▼|MDLZ61.29-1.16 (-1.86%) ▼|MDT92.41+0.23 (+0.24%) ▲|META618.98+26.13 (+4.41%) ▲|MMM167.34-1.41 (-0.84%) ▼|MO69.78+0.22 (+0.32%) ▲|MRK150.44-1.20 (-0.79%) ▼|MS216.99+5.17 (+2.44%) ▲|MSFT512.81+15.99 (+3.22%) ▲|MU945.27-10.81 (-1.13%) ▼|NEE84.11+1.01 (+1.21%) ▲|NFLX82.56-0.17 (-0.21%) ▼|NKE38.21-0.03 (-0.07%) ▼|NOW143.79+7.07 (+5.17%) ▲|NVDA226.98+2.57 (+1.14%) ▲|ORCL152.30+6.55 (+4.49%) ▲|PEP139.66-0.87 (-0.62%) ▼|PFE28.73-0.30 (-1.02%) ▼|PG147.15-0.49 (-0.33%) ▼|PLTR183.42+13.96 (+8.24%) ▲|PM188.56+0.62 (+0.33%) ▲|QCOM169.19+0.15 (+0.09%) ▲|RTX201.25+0.47 (+0.23%) ▲|SBUX106.03-0.69 (-0.65%) ▼|SCHW110.10+1.86 (+1.71%) ▲|SO89.07+0.76 (+0.86%) ▲|SPG211.54+1.34 (+0.64%) ▲|T25.89-0.07 (-0.25%) ▼|TMO611.47+2.93 (+0.48%) ▲|TMUS188.01+0.71 (+0.38%) ▲|TSLA380.40+23.39 (+6.55%) ▲|TXN252.48-2.32 (-0.91%) ▼|UBER75.60-0.86 (-1.12%) ▼|UNH404.94+5.28 (+1.32%) ▲|UNP290.56+0.83 (+0.29%) ▲|UPS102.78-0.23 (-0.22%) ▼|USB63.38+0.61 (+0.96%) ▲|V379.41+1.01 (+0.27%) ▲|VZ50.21-0.01 (-0.02%) ▼|WFC89.61+0.34 (+0.38%) ▲|WMT108.98+2.89 (+2.72%) ▲|XOM164.38+0.23 (+0.14%) ▲|AAPL330.49+5.53 (+1.70%) ▲|ABBV260.68-1.04 (-0.40%) ▼|ABT108.84-1.63 (-1.48%) ▼|ACN193.90+6.22 (+3.31%) ▲|ADBE286.31+6.52 (+2.33%) ▲|AMAT435.32-3.14 (-0.72%) ▼|AMD455.80-1.26 (-0.28%) ▼|AMGN442.90+0.06 (+0.01%) ▲|AMT177.25+4.33 (+2.50%) ▲|AMZN258.65+3.67 (+1.44%) ▲|AVGO347.54-19.70 (-5.36%) ▼|AXP330.52+0.54 (+0.16%) ▲|BA207.07-1.80 (-0.86%) ▼|BAC63.11+0.51 (+0.81%) ▲|BKNG198.54-1.06 (-0.53%) ▼|BLK1,116.05+8.97 (+0.81%) ▲|BMY67.55-0.12 (-0.17%) ▼|BNY164.22+2.18 (+1.34%) ▲|BRK-B507.61+2.37 (+0.47%) ▲|C137.73+3.39 (+2.52%) ▲|CAT801.00+8.72 (+1.10%) ▲|CL90.27+0.17 (+0.19%) ▲|CMCSA26.59-0.23 (-0.84%) ▼|COF218.97+2.37 (+1.09%) ▲|COP137.07-0.13 (-0.09%) ▼|COST927.05-1.43 (-0.15%) ▼|CRM264.22+7.29 (+2.84%) ▲|CSCO109.37-0.09 (-0.08%) ▼|CVS97.60+0.37 (+0.38%) ▲|CVX213.02+1.24 (+0.59%) ▲|DE692.91-5.46 (-0.78%) ▼|DHR208.92-0.99 (-0.47%) ▼|DIS107.82-0.16 (-0.15%) ▼|DUK121.56+1.00 (+0.83%) ▲|EMR149.58+0.60 (+0.40%) ▲|FDX320.38+3.84 (+1.21%) ▲|GD362.48-1.59 (-0.44%) ▼|GE332.37+2.87 (+0.87%) ▲|GEV945.25+23.31 (+2.53%) ▲|GILD149.98+0.37 (+0.24%) ▲|GM86.26+1.39 (+1.64%) ▲|GOOG339.54+5.76 (+1.73%) ▲|GOOGL343.03+5.91 (+1.75%) ▲|GS1,036.64+32.22 (+3.21%) ▲|HD317.86+1.68 (+0.53%) ▲|HON206.83+0.76 (+0.37%) ▲|IBM235.25+3.55 (+1.53%) ▲|INTC90.14+0.09 (+0.10%) ▲|INTU349.34+6.40 (+1.87%) ▲|ISRG368.79-3.09 (-0.83%) ▼|JNJ278.07+2.86 (+1.04%) ▲|JPM361.62+5.40 (+1.52%) ▲|KO88.92+0.68 (+0.77%) ▲|LIN483.75-2.10 (-0.43%) ▼|LLY1,152.68-7.41 (-0.64%) ▼|LMT530.78-0.77 (-0.14%) ▼|LOW200.94+1.10 (+0.55%) ▲|LRCX286.57-1.75 (-0.61%) ▼|MA587.11-1.04 (-0.18%) ▼|MCD258.47-2.48 (-0.95%) ▼|MDLZ61.29-1.16 (-1.86%) ▼|MDT92.41+0.23 (+0.24%) ▲|META618.98+26.13 (+4.41%) ▲|MMM167.34-1.41 (-0.84%) ▼|MO69.78+0.22 (+0.32%) ▲|MRK150.44-1.20 (-0.79%) ▼|MS216.99+5.17 (+2.44%) ▲|MSFT512.81+15.99 (+3.22%) ▲|MU945.27-10.81 (-1.13%) ▼|NEE84.11+1.01 (+1.21%) ▲|NFLX82.56-0.17 (-0.21%) ▼|NKE38.21-0.03 (-0.07%) ▼|NOW143.79+7.07 (+5.17%) ▲|NVDA226.98+2.57 (+1.14%) ▲|ORCL152.30+6.55 (+4.49%) ▲|PEP139.66-0.87 (-0.62%) ▼|PFE28.73-0.30 (-1.02%) ▼|PG147.15-0.49 (-0.33%) ▼|PLTR183.42+13.96 (+8.24%) ▲|PM188.56+0.62 (+0.33%) ▲|QCOM169.19+0.15 (+0.09%) ▲|RTX201.25+0.47 (+0.23%) ▲|SBUX106.03-0.69 (-0.65%) ▼|SCHW110.10+1.86 (+1.71%) ▲|SO89.07+0.76 (+0.86%) ▲|SPG211.54+1.34 (+0.64%) ▲|T25.89-0.07 (-0.25%) ▼|TMO611.47+2.93 (+0.48%) ▲|TMUS188.01+0.71 (+0.38%) ▲|TSLA380.40+23.39 (+6.55%) ▲|TXN252.48-2.32 (-0.91%) ▼|UBER75.60-0.86 (-1.12%) ▼|UNH404.94+5.28 (+1.32%) ▲|UNP290.56+0.83 (+0.29%) ▲|UPS102.78-0.23 (-0.22%) ▼|USB63.38+0.61 (+0.96%) ▲|V379.41+1.01 (+0.27%) ▲|VZ50.21-0.01 (-0.02%) ▼|WFC89.61+0.34 (+0.38%) ▲|WMT108.98+2.89 (+2.72%) ▲|XOM164.38+0.23 (+0.14%) ▲|
25.1 C
New York
Thursday, September 3, 2026

Tag: patients

newssourceFORcompanyinformationcontent1releasesmarket

Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability, Proving the Strength of Its Drug-Delivery Platform

More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and setting a new...

Oxehealth Rebrands as LIO, Launching Next-Gen Platform to Transform Inpatient Mental Health Care

New capabilities boost patient experience and safety, reduce clinician burden and unlock operational insight across hospitals OXFORD, England, Aug. 13, 2025 /PRNewswire/ -- Oxehealth, a...

Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunity

Greywolf starts first trial of GRWD0715, aiming for a functional cure for autoimmunity by targeting its antigenic source.

Santhera Secures Agreement with GEN for the Distribution of AGAMREE® (Vamorolone) in Türkiye

Pratteln, Switzerland, 13 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for the distribution and promotion of AGAMREE® (vamorolone) in Türkiye for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.

HopeAI Joins Mayo Clinic Platform to Transform the Future of Drug Development with AI

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- HopeAI, an emerging leader in applying artificial intelligence (AI) to accelerate new drug development, has officially joined...

KBP’s Contest of Injunction Obtained by Novo Nordisk Continues in Arbitration

SINGAPORE, Aug. 13, 2025 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company") today issued a statement addressing a further decision by the Singapore International...

Second heartbeat

BEIJING, Aug. 12, 2025 /PRNewswire/ -- A news report from chinadaily.com.cn In this documentary, three patients suffered from advanced heart failure share their stories of how...

Study Reveals How Small Changes in Walking Technique May Help Treat Knee Osteoarthritis

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Gait analysis and pain measures show that subtly adjusting the angle of the foot during walking may...

MindHYVE.ai Partners with ICS Pakistan and NEI Pakistan to Revolutionize Nursing Education with AI-Powered ArthurAI

ISLAMABAD, Aug. 12, 2025 /PRNewswire/ --In a pioneering step towards elevating nursing education in Pakistan, MindHYVE.ai has signed strategic Memorandum of Understanding (MoU) with...

Global Digital Health Market Poised for Robust Growth at a CAGR of ~18% by 2032 Amid Rising Demand for Remote Care| DelveInsight

The digital health market is experiencing robust growth, driven by increasing adoption of telemedicine, wearable devices, and AI-powered health solutions. Rising healthcare costs and...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2025 and provided a business update. All dollar values are in U.S. dollars unless stated otherwise.

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02 LOS...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatients

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers